199 related articles for article (PubMed ID: 34105360)
21. Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.
Fabrizi F; Tripodi F; Cerutti R; Nardelli L; Alfieri CM; Donato MF; Castellano G
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423179
[TBL] [Abstract][Full Text] [Related]
22. Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
Liu CJ; Tseng KC; Lo CC; Tseng IH; Cheng PN
J Formos Med Assoc; 2020 May; 119(5):933-940. PubMed ID: 31594667
[TBL] [Abstract][Full Text] [Related]
23. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
24. Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
Kim NG; Kullar R; Khalil H; Saab S
J Viral Hepat; 2020 Aug; 27(8):762-769. PubMed ID: 32386099
[TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Belperio PS; Shahoumian TA; Loomis TP; Backus LI
J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
Chen P; Jin M; Cao Y; Li H
Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis.
Indolfi G; Easterbrook P; Giometto S; Malik F; Chou R; Lucenteforte E
Liver Int; 2024 Mar; 44(3):663-681. PubMed ID: 38293756
[TBL] [Abstract][Full Text] [Related]
29. Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report.
Naganuma A; Sato K; Fukuchi T; Namikawa M; Kakizaki S; Uraoka T; Ohnishi H; Okamoto H
Clin J Gastroenterol; 2019 Dec; 12(6):592-597. PubMed ID: 31376076
[TBL] [Abstract][Full Text] [Related]
30. Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine.
Amjad W; Zhang T; Maheshwari A; Thuluvath PJ
J Clin Exp Hepatol; 2022; 12(2):329-335. PubMed ID: 35535089
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
32. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
34. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
[TBL] [Abstract][Full Text] [Related]
35. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.
Langness JA; Nguyen M; Wieland A; Everson GT; Kiser JJ
World J Gastroenterol; 2017 Mar; 23(9):1618-1626. PubMed ID: 28321163
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
[TBL] [Abstract][Full Text] [Related]
37. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
38. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics.
Zarębska-Michaluk D; Jaroszewicz J; Parfieniuk-Kowerda A; Janczewska E; Dybowska D; Pawłowska M; Halota W; Mazur W; Lorenc B; Janocha-Litwin J; Simon K; Piekarska A; Berak H; Klapaczyński J; Stępień P; Sobala-Szczygieł B; Citko J; Socha Ł; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Dobracka B; Krygier R; Białkowska-Warzecha J; Laurans Ł; Flisiak R
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362064
[TBL] [Abstract][Full Text] [Related]
40. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Devan P; Tiong KLA; Neo JE; Mohan BP; Wijarnpreecha K; Tam YCS; Coppola N; Preda CM; Wong YJ
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
